|
|
Article: Cancer therapeutics development company files IND for metastatic breast cancer.
- Article from:
- Blood Weekly
- Article date:
- August 5, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 AUG 5 - (NewsRx.com & NewsRx.net) -- NeoRx Corporation (Nasdaq:NERX) announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a phase II clinical study of STR (skeletal targeted radiotherapy) in patients with breast cancer that has metastasized to the bone.
Researchers at Houston-based M.D. Anderson Cancer Center have conducted a small investigator-initiated phase I dose-escalation study of STR in patients with stage IV breast cancer involving osseous (bony) metastases. Six patients were administered STR as a single agent, followed by autologous (self-donor) blood stem cell transplantation. ...
Related newspaper, magazine, and journal articles:
|
|
Article: New breast cancer findings from F. Montemurro and ...
Anti-Infectives Week;
December 22, 2008 ;
700+ words
... ... HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab ... Lapatinib Era. Clinical Breast Cancer, 2008;8(5):436 ... Division Oncology Media, Str Prov 142, I-10060 ... the journal Clinical Breast Cancer can be contacted at ...
|
|